Gabriela Chiosis - Publications

Weill Cornell Medical College, New York, NY, United States 
Biomedical Engineering, Biochemistry

128 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Pillarsetty N, Jhaveri K, Taldone T, Caldas-Lopes E, Punzalan B, Joshi S, Bolaender A, Uddin MM, Rodina A, Yan P, Ku A, Ku T, Shah SK, Lyashchenko S, Burnazi E, ... ... Chiosis G, et al. Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer Cell. PMID 31668946 DOI: 10.1016/j.ccell.2019.09.007  0.72
2019 Taldone T, Wang T, Rodina A, Pillarsetty NVK, Digwal CS, Sharma S, Yan P, Joshi S, Pagare PP, Bolaender A, Roboz GJ, Guzman ML, Chiosis G. A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond. Cold Spring Harbor Perspectives in Biology. PMID 30936118 DOI: 10.1101/cshperspect.a034116  0.72
2018 Wang T, Rodina A, Dunphy MP, Corben A, Modi S, Guzman ML, Gewirth DT, Chiosis G. Chaperome heterogeneity and its implications for cancer study and treatment. The Journal of Biological Chemistry. PMID 30409908 DOI: 10.1074/jbc.REV118.002811  0.72
2018 Kishinevsky S, Wang T, Rodina A, Chung SY, Xu C, Philip J, Taldone T, Joshi S, Alpaugh ML, Bolaender A, Gutbier S, Sandhu D, Fattahi F, Zimmer B, Shah SK, ... ... Chiosis G, et al. HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. Nature Communications. 9: 4345. PMID 30341316 DOI: 10.1038/s41467-018-06486-6  0.72
2017 Giulino-Roth L, Van Besien HJ, Dalton T, Totonchy JE, Rodina A, Taldone T, Bolaender A, Erdjument-Bromage H, Sadek J, Chadburn A, Barth MJ, Dela Cruz FS, Rainey A, Kung AL, Chiosis G, et al. Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma. Molecular Cancer Therapeutics. PMID 28619753 DOI: 10.1158/1535-7163.MCT-16-0848  0.72
2016 Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, ... ... Chiosis G, et al. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. PMID 27706135 DOI: 10.1038/nature19807  0.72
2016 Chiosis G. Editorial: Heat Shock Protein in Disease - From Molecular Mechanisms to Therapeutics. Current Topics in Medicinal Chemistry. PMID 27142687 DOI: 10.2174/156802606777812022  0.72
2016 Shrestha L, Patel HJ, Chiosis G. Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease. Cell Chemical Biology. 23: 158-72. PMID 26933742 DOI: 10.1016/j.chembiol.2015.12.006  0.72
2016 Taldone T, Zatorska D, Ochiana SO, Smith-Jones P, Koziorowski J, Dunphy MP, Zanzonico P, Bolaender A, Lewis JS, Larson SM, Chiosis G, Pillarsetty NV. Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71. Journal of Labelled Compounds & Radiopharmaceuticals. PMID 26806023 DOI: 10.1002/jlcr.3369  0.72
2015 Zong H, Gozman A, Caldas-Lopes E, Taldone T, Sturgill E, Brennan S, Ochiana SO, Gomes-DaGama EM, Sen S, Rodina A, Koren J, Becker MW, Rudin CM, Melnick A, Levine RL, ... ... Chiosis G, et al. A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell Reports. PMID 26628369 DOI: 10.1016/j.celrep.2015.10.073  0.72
2015 Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL, Patel J, Taldone T, Chiosis G, Ladetto M, Ghione P, et al. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood. PMID 26603836 DOI: 10.1182/blood-2015-05-645069  0.72
2015 Kaittanis C, Shaffer TM, Bolaender A, Appelbaum Z, Appelbaum J, Chiosis G, Grimm J. Multifunctional MRI/PET Nanobeacons Derived from the In situ Self-Assembly of Translational Polymers and Clinical Cargo through Coalescent Intermolecular Forces. Nano Letters. PMID 26540670 DOI: 10.1021/acs.nanolett.5b03370  0.72
2015 Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, Cerchietti L, Melnick A. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. The Journal of Clinical Investigation. 2015. PMID 26529251 DOI: 10.1172/JCI80714  0.72
2015 Carney B, Carlucci G, Salinas B, Di Gialleonardo V, Kossatz S, Vansteene A, Longo VA, Bolaender A, Chiosis G, Keshari KR, Weber WA, Reiner T. Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 26493053 DOI: 10.1007/s11307-015-0904-y  0.72
2015 Kucine N, Marubayashi S, Bhagwat N, Papalexi E, Koppikar P, Sanchez Martin M, Dong L, Tallman MS, Paietta E, Wang K, He J, Lipson D, Stephens P, Miller V, Rowe JM, ... ... Chiosis G, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. PMID 26443624 DOI: 10.1182/blood-2015-03-635821  0.72
2015 Salinas B, Irwin CP, Kossatz S, Bolaender A, Chiosis G, Pillarsetty N, Weber WA, Reiner T. Radioiodinated PARP1 tracers for glioblastoma imaging. Ejnmmi Research. 5: 123. PMID 26337803 DOI: 10.1186/s13550-015-0123-1  0.72
2015 Needham PG, Patel HJ, Chiosis G, Thibodeau PH, Brodsky JL. Mutations in the Yeast Hsp70, Ssa1, at P417 Alter ATP Cycling, Interdomain Coupling, and Specific Chaperone Functions. Journal of Molecular Biology. PMID 25913688 DOI: 10.1016/j.jmb.2015.04.010  0.72
2015 Patel HJ, Patel PD, Ochiana SO, Yan P, Sun W, Patel MR, Shah SK, Tramentozzi E, Brooks J, Bolaender A, Shrestha L, Stephani R, Finotti P, Leifer C, Li Z, ... ... Chiosis G, et al. Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94. Journal of Medicinal Chemistry. 58: 3922-43. PMID 25901531 DOI: 10.1021/acs.jmedchem.5b00197  0.72
2015 Rachidi S, Sun S, Wu BX, Jones E, Drake RR, Ogretmen B, Cowart LA, Clarke CJ, Hannun YA, Chiosis G, Liu B, Li Z. Endoplasmic reticulum heat shock protein gp96 maintains liver homeostasis and promotes hepatocellular carcinogenesis. Journal of Hepatology. 62: 879-88. PMID 25463537 DOI: 10.1016/j.jhep.2014.11.010  0.72
2014 Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney AS, Chiosis G, Chung YR, Pandey S, van den Brink MR, Armstrong SA, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America. 111: E5401-10. PMID 25516983 DOI: 10.1073/pnas.1407792111  0.72
2014 Chan CT, Qi J, Smith W, Paranol R, Mazitschek R, West N, Reeves R, Chiosis G, Schreiber SL, Bradner JE, Paulmurugan R, Gambhir SS. Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects. Cancer Research. 74: 7475-86. PMID 25320008 DOI: 10.1158/0008-5472.CAN-14-0197  0.72
2014 Azoitei N, Diepold K, Brunner C, Rouhi A, Genze F, Becher A, Kestler H, van Lint J, Chiosis G, Koren J, Fröhling S, Scholl C, Seufferlein T. HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization. Cancer Research. 74: 7125-36. PMID 25297628 DOI: 10.1158/0008-5472.CAN-14-1017  0.72
2014 Taldone T, Ochiana SO, Patel PD, Chiosis G. Selective targeting of the stress chaperome as a therapeutic strategy. Trends in Pharmacological Sciences. 35: 592-603. PMID 25262919 DOI: 10.1016/  0.72
2014 Rodina A, Taldone T, Kang Y, Patel PD, Koren J, Yan P, DaGama Gomes EM, Yang C, Patel MR, Shrestha L, Ochiana SO, Santarossa C, Maharaj R, Gozman A, Cox MB, ... ... Chiosis G, et al. Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. Acs Chemical Biology. 9: 1698-705. PMID 24934503 DOI: 10.1021/cb500256u  0.72
2014 Taldone T, Patel HJ, Bolaender A, Patel MR, Chiosis G. Protein chaperones: a composition of matter review (2008 - 2013). Expert Opinion On Therapeutic Patents. 24: 501-18. PMID 24742089 DOI: 10.1517/13543776.2014.887681  0.72
2014 Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-DaGama EM, Koren J, Modi S, Chiosis G. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opinion On Investigational Drugs. 23: 611-28. PMID 24669860 DOI: 10.1517/13543784.2014.902442  0.72
2014 Kaittanis C, Shaffer TM, Ogirala A, Santra S, Perez JM, Chiosis G, Li Y, Josephson L, Grimm J. Environment-responsive nanophores for therapy and treatment monitoring via molecular MRI quenching. Nature Communications. 5: 3384. PMID 24594970 DOI: 10.1038/ncomms4384  0.72
2014 Taldone T, Kang Y, Patel HJ, Patel MR, Patel PD, Rodina A, Patel Y, Gozman A, Maharaj R, Clement CC, Lu A, Young JC, Chiosis G. Heat shock protein 70 inhibitors. 2. 2,5'-thiodipyrimidines, 5-(phenylthio)pyrimidines, 2-(pyridin-3-ylthio)pyrimidines, and 3-(phenylthio)pyridines as reversible binders to an allosteric site on heat shock protein 70. Journal of Medicinal Chemistry. 57: 1208-24. PMID 24548239 DOI: 10.1021/jm401552y  0.72
2014 Kang Y, Taldone T, Patel HJ, Patel PD, Rodina A, Gozman A, Maharaj R, Clement CC, Patel MR, Brodsky JL, Young JC, Chiosis G. Heat shock protein 70 inhibitors. 1. 2,5'-thiodipyrimidine and 5-(phenylthio)pyrimidine acrylamides as irreversible binders to an allosteric site on heat shock protein 70. Journal of Medicinal Chemistry. 57: 1188-207. PMID 24548207 DOI: 10.1021/jm401551n  0.72
2014 Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, Qi J, Kleppe M, Patel HJ, Shah SK, Taldone T, Bradner JE, Chiosis G, Levine RL. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. 123: 2075-83. PMID 24470592 DOI: 10.1182/blood-2014-01-547760  0.72
2014 Ambati SR, Lopes EC, Kosugi K, Mony U, Zehir A, Shah SK, Taldone T, Moreira AL, Meyers PA, Chiosis G, Moore MA. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. Molecular Oncology. 8: 323-36. PMID 24388362 DOI: 10.1016/j.molonc.2013.12.005  0.72
2013 Rodina A, Patel PD, Kang Y, Patel Y, Baaklini I, Wong MJ, Taldone T, Yan P, Yang C, Maharaj R, Gozman A, Patel MR, Patel HJ, Chirico W, Erdjument-Bromage H, ... ... Chiosis G, et al. Identification of an allosteric pocket on human hsp70 reveals a mode of inhibition of this therapeutically important protein. Chemistry & Biology. 20: 1469-80. PMID 24239008 DOI: 10.1016/j.chembiol.2013.10.008  0.72
2013 Shahinas D, Folefoc A, Taldone T, Chiosis G, Crandall I, Pillai DR. A purine analog synergizes with chloroquine (CQ) by targeting Plasmodium falciparum Hsp90 (PfHsp90). Plos One. 8: e75446. PMID 24098696 DOI: 10.1371/journal.pone.0075446  0.72
2013 Hua Y, White-Gilbertson S, Kellner J, Rachidi S, Usmani SZ, Chiosis G, Depinho R, Li Z, Liu B. Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma Clinical Cancer Research. 19: 6242-6251. PMID 24077352 DOI: 10.1158/1078-0432.CCR-13-2083  0.72
2013 Patel PD, Yan P, Seidler PM, Patel HJ, Sun W, Yang C, Que NS, Taldone T, Finotti P, Stephani RA, Gewirth DT, Chiosis G. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nature Chemical Biology. 9: 677-84. PMID 23995768 DOI: 10.1038/nchembio.1335  0.72
2013 Taldone T, Patel PD, Patel M, Patel HJ, Evans CE, Rodina A, Ochiana S, Shah SK, Uddin M, Gewirth D, Chiosis G. Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series. Journal of Medicinal Chemistry. 56: 6803-18. PMID 23965125 DOI: 10.1021/jm400619b  0.72
2013 Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL, Cesarman E. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 122: 2837-47. PMID 23943653 DOI: 10.1182/blood-2013-01-479972  0.72
2013 Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G, Neckers L. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors. Oncotarget. 4: 1065-74. PMID 23867252  0.72
2013 Hong F, Liu B, Chiosis G, Gewirth DT, Li Z. α7 helix region of αI domain is crucial for integrin binding to endoplasmic reticulum chaperone gp96: a potential therapeutic target for cancer metastasis. The Journal of Biological Chemistry. 288: 18243-8. PMID 23671277 DOI: 10.1074/jbc.M113.468850  0.72
2013 Taldone T, Rodina A, Dagama Gomes EM, Riolo M, Patel HJ, Alonso-Sabadell R, Zatorska D, Patel MR, Kishinevsky S, Chiosis G. Synthesis and evaluation of cell-permeable biotinylated PU-H71 derivatives as tumor Hsp90 probes. Beilstein Journal of Organic Chemistry. 9: 544-56. PMID 23616796 DOI: 10.3762/bjoc.9.60  0.72
2013 Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 936-43. PMID 23578997 DOI: 10.2967/jnumed.112.110239  0.72
2013 Chiosis G, Dickey CA, Johnson JL. A global view of Hsp90 functions. Nature Structural & Molecular Biology. 20: 1-4. PMID 23288357 DOI: 10.1038/nsmb.2481  0.72
2013 Lisi L, McGuire S, Sharp A, Chiosis G, Navarra P, Feinstein DL, Dello Russo C. The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE. Journal of Neuroimmunology. 255: 1-7. PMID 23123171 DOI: 10.1016/j.jneuroim.2012.10.008  0.72
2013 Taldone T, Zatorska D, Patel HJ, Sun W, Patel MR, Chiosis G. Preparation of a diverse purine-scaffold library via one-step palladium catalyzed cross-coupling Heterocycles. 87: 91-113. DOI: 10.3987/COM-12-12613  0.72
2012 Chan CT, Reeves RE, Geller R, Yaghoubi SS, Hoehne A, Solow-Cordero DE, Chiosis G, Massoud TF, Paulmurugan R, Gambhir SS. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects. Proceedings of the National Academy of Sciences of the United States of America. 109: E2476-85. PMID 22895790 DOI: 10.1073/pnas.1205459109  0.72
2012 Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, ... ... Chiosis G, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 489: 155-9. PMID 22820254 DOI: 10.1038/nature11303  0.72
2012 Brooks JC, Sun W, Chiosis G, Leifer CA. Heat shock protein gp96 regulates Toll-like receptor 9 proteolytic processing and conformational stability. Biochemical and Biophysical Research Communications. 421: 780-4. PMID 22554506 DOI: 10.1016/j.bbrc.2012.04.083  0.72
2012 Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, et al. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. The Journal of Experimental Medicine. 209: 697-711. PMID 22451720 DOI: 10.1084/jem.20111910  0.72
2012 Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochimica Et Biophysica Acta. 1823: 742-55. PMID 22062686 DOI: 10.1016/j.bbamcr.2011.10.008  0.72
2012 Taldone T, Zatorska D, Chiosis G. Reaction of 2-naphthylamine with sodium iodate/sodium sulfite: Synthesis of 2-amino-1-iodonaphthalene Synthetic Communications. 42: 635-638. DOI: 10.1080/00397911.2010.528290  0.72
2012 Taldone T, Patel PD, Patel HJ, Chiosis G. About the reaction of aryl fluorides with sodium sulfide: Investigation into the selectivity of substitution of fluorobenzonitriles to yield mercaptobenzonitriles via S NAr displacement of fluorine Tetrahedron Letters. 53: 2548-2551. DOI: 10.1016/j.tetlet.2012.03.032  0.72
2011 Patel HJ, Modi S, Chiosis G, Taldone T. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opinion On Drug Discovery. 6: 559-587. PMID 22400044 DOI: 10.1517/17460441.2011.563296  0.72
2011 Usmani SZ, Chiosis G. HSP90 inhibitors as therapy for multiple myeloma. Clinical Lymphoma, Myeloma & Leukemia. 11: S77-81. PMID 22035754 DOI: 10.1016/j.clml.2011.03.027  0.72
2011 Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... ... Chiosis G, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chemical Biology. 7: 818-26. PMID 21946277 DOI: 10.1038/nchembio.670  0.72
2011 Taldone T, Gomes-DaGama EM, Zong H, Sen S, Alpaugh ML, Zatorska D, Alonso-Sabadell R, Guzman ML, Chiosis G. Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy. Bioorganic & Medicinal Chemistry Letters. 21: 5347-52. PMID 21802945 DOI: 10.1016/j.bmcl.2011.07.026  0.72
2011 Taldone T, Zatorska D, Patel PD, Zong H, Rodina A, Ahn JH, Moulick K, Guzman ML, Chiosis G. Design, synthesis, and evaluation of small molecule Hsp90 probes. Bioorganic & Medicinal Chemistry. 19: 2603-14. PMID 21459002 DOI: 10.1016/j.bmc.2011.03.013  0.72
2011 Breinig M, Mayer P, Harjung A, Goeppert B, Malz M, Penzel R, Neumann O, Hartmann A, Dienemann H, Giaccone G, Schirmacher P, Kern MA, Chiosis G, Rieker RJ. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2237-49. PMID 21372220 DOI: 10.1158/1078-0432.CCR-10-1689  0.72
2011 Ahn JH, Luo W, Kim J, Rodina A, Clement CC, Aguirre J, Sun W, Kang Y, Maharaj R, Moulick K, Zatorska D, Kokoszka M, Brodsky JL, Chiosis G. Design of a flexible cell-based assay for the evaluation of heat shock protein 70 expression modulators. Assay and Drug Development Technologies. 9: 236-46. PMID 21133677 DOI: 10.1089/adt.2010.0327  0.72
2011 Sun W, Patel PD, Stephani RA, Chiosis G. An efficient copper-catalyzed microwave-assisted S-arylation towards the synthesis of 8-arylsulfanyl adenines Synlett. 3008-3012. DOI: 10.1055/s-0031-1289888  0.72
2010 Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. The Journal of Clinical Investigation. 120: 4569-82. PMID 21041953 DOI: 10.1172/JCI42869  0.72
2010 Usmani SZ, Bona RD, Chiosis G, Li Z. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. Journal of Hematology & Oncology. 3: 40. PMID 20977755 DOI: 10.1186/1756-8722-3-40  0.72
2010 Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes E, Ross KN, Gönen M, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, ... ... Chiosis G, et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans Journal of Clinical Investigation. 120: 3578-3593. PMID 20852385 DOI: 10.1172/JCI42442  0.72
2010 Taldone T, Gillan V, Sun W, Rodina A, Patel P, Maitland K, O'Neill K, Chiosis G, Devaney E. Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90. Plos Neglected Tropical Diseases. 4: e714. PMID 20559560 DOI: 10.1371/journal.pntd.0000714  0.72
2010 Luo W, Sun W, Taldone T, Rodina A, Chiosis G. Heat shock protein 90 in neurodegenerative diseases. Molecular Neurodegeneration. 5: 24. PMID 20525284 DOI: 10.1186/1750-1326-5-24  0.72
2010 Wrona IE, Gozman A, Taldone T, Chiosis G, Panek JS. Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: Potent inhibitors of heat shock protein 90 Journal of Organic Chemistry. 75: 2820-2835. PMID 20392070 DOI: 10.1021/jo1000109  0.72
2010 Holland JP, Caldas-Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, Chiosis G, Lewis JS. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. Plos One. 5: e8859. PMID 20111600 DOI: 10.1371/journal.pone.0008859  0.72
2010 Taldone T, Zatorska D, Kang Y, Chiosis G. A facile and efficient synthesis of d6-labeled PU-H71, a purine-scaffold Hsp90 inhibitor Journal of Labelled Compounds and Radiopharmaceuticals. 53: 47-49. DOI: 10.1002/jlcr.1689  0.72
2009 Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nature Medicine. 15: 1369-76. PMID 19966776 DOI: 10.1038/nm.2059  0.72
2009 Taldone T, Chiosis G. Purine-scaffold Hsp90 inhibitors. Current Topics in Medicinal Chemistry. 9: 1436-46. PMID 19860732 DOI: 10.2174/156802609789895737  0.72
2009 Breinig M, Caldas-Lopes E, Goeppert B, Malz M, Rieker R, Bergmann F, Schirmacher P, Mayer M, Chiosis G, Kern MA. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology (Baltimore, Md.). 50: 102-12. PMID 19441108 DOI: 10.1002/hep.22912  0.72
2009 Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, ... ... Chiosis G, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America. 106: 8368-73. PMID 19416831 DOI: 10.1073/pnas.0903392106  0.72
2009 Chiosis G, Keeton AB. Assay for isolation of inhibitors of her2-kinase expression. Methods in Molecular Biology (Clifton, N.J.). 486: 139-49. PMID 19347621 DOI: 10.1007/978-1-60327-545-3_10  0.72
2009 Tao H, Kang Y, Taldone T, Chiosis G. Microwave-assisted one step synthesis of 8-arylmethyl-9H-purin-6-amines. Bioorganic & Medicinal Chemistry Letters. 19: 415-7. PMID 19058963 DOI: 10.1016/j.bmcl.2008.11.057  0.72
2009 Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorganic & Medicinal Chemistry. 17: 2225-35. PMID 19017562 DOI: 10.1016/j.bmc.2008.10.087  0.72
2008 Chiosis G, Kang Y, Sun W. Discovery and development of purine-scaffold Hsp90 inhibitors. Expert Opinion On Drug Discovery. 3: 99-114. PMID 23480142 DOI: 10.1517/17460441.3.1.99  0.72
2008 Luo W, Rodina A, Chiosis G. Heat shock protein 90: translation from cancer to Alzheimer's disease treatment? Bmc Neuroscience. 9: S7. PMID 19090995 DOI: 10.1186/1471-2202-9-S2-S7  0.72
2008 Lopes EC, Valls E, Figueroa ME, Mazur A, Meng FG, Chiosis G, Laird PW, Schreiber-Agus N, Greally JM, Prokhortchouk E, Melnick A. Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. Cancer Research. 68: 7258-63. PMID 18794111 DOI: 10.1158/0008-5472.CAN-08-0344  0.72
2008 Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Current Opinion in Pharmacology. 8: 370-4. PMID 18644253 DOI: 10.1016/j.coph.2008.06.015  0.72
2008 Ganesh T, Min J, Thepchatri P, Du Y, Li L, Lewis I, Wilson L, Fu H, Chiosis G, Dingledine R, Liotta D, Snyder JP, Sun A. Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling. Bioorganic & Medicinal Chemistry. 16: 6903-10. PMID 18571929 DOI: 10.1016/j.bmc.2008.05.047  0.72
2008 Goeckeler JL, Petruso AP, Aguirre J, Clement CC, Chiosis G, Brodsky JL. The yeast Hsp110, Sse1p, exhibits high-affinity peptide binding. Febs Letters. 582: 2393-6. PMID 18539149 DOI: 10.1016/j.febslet.2008.05.047  0.72
2008 Kang Y, Taldone T, Clement CC, Fewell SW, Aguirre J, Brodsky JL, Chiosis G. Design of a fluorescence polarization assay platform for the study of human Hsp70. Bioorganic & Medicinal Chemistry Letters. 18: 3749-51. PMID 18515098 DOI: 10.1016/j.bmcl.2008.05.046  0.72
2008 Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang WJ, Moore DJ, Dawson TM, Dawson VL, Chiosis G, Cookson MR, et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 3384-91. PMID 18367605 DOI: 10.1523/JNEUROSCI.0185-08.2008  0.72
2008 Didelot C, Lanneau D, Brunet M, Bouchot A, Cartier J, Jacquel A, Ducoroy P, Cathelin S, Decologne N, Chiosis G, Dubrez-Daloz L, Solary E, Garrido C. Interaction of heat-shock protein 90β isoform (HSP90β) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation Cell Death and Differentiation. 15: 859-866. PMID 18239673 DOI: 10.1038/cdd.2008.5  0.72
2008 Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discovery Today. 13: 38-43. PMID 18190862 DOI: 10.1016/j.drudis.2007.10.007  0.72
2008 Chan CT, Paulmurugan R, Gheysens OS, Kim J, Chiosis G, Gambhir SS. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects. Cancer Research. 68: 216-26. PMID 18172314 DOI: 10.1158/0008-5472.CAN-07-2268  0.72
2007 Didelot C, Lanneau D, Brunet M, Joly AL, De Thonel A, Chiosis G, Garrido C. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Current Medicinal Chemistry. 14: 2839-47. PMID 18045130 DOI: 10.2174/092986707782360079  0.72
2007 Du Y, Moulick K, Rodina A, Aguirre J, Felts S, Dingledine R, Fu H, Chiosis G. High-throughput screening fluorescence polarization assay for tumor-specific Hsp90. Journal of Biomolecular Screening. 12: 915-24. PMID 17942784 DOI: 10.1177/1087057107306067  0.72
2007 Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, Chiang A, Litz J, Clement CC, Kang Y, She Y, Wu N, Felts S, Wipf P, Massague J, Jiang X, ... ... Chiosis G, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nature Chemical Biology. 3: 498-507. PMID 17603540 DOI: 10.1038/nchembio.2007.10  0.72
2007 Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, Chiosis G. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proceedings of the National Academy of Sciences of the United States of America. 104: 9511-6. PMID 17517623 DOI: 10.1073/pnas.0701055104  0.72
2006 Chiosis G, Neckers L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. Acs Chemical Biology. 1: 279-84. PMID 17163756 DOI: 10.1021/cb600224w  0.72
2006 Chiosis G, Tao H. Purine-scaffold Hsp90 inhibitors. Idrugs : the Investigational Drugs Journal. 9: 778-82. PMID 17096299  0.72
2006 Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 10: 321-30. PMID 17010675 DOI: 10.1016/j.ccr.2006.09.005  0.72
2006 Immormino RM, Kang Y, Chiosis G, Gewirth DT. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. Journal of Medicinal Chemistry. 49: 4953-60. PMID 16884307 DOI: 10.1021/jm060297x  0.72
2006 Brodsky JL, Chiosis G. Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators. Current Topics in Medicinal Chemistry. 6: 1215-25. PMID 16842158 DOI: 10.2174/156802606777811997  0.72
2006 Chiosis G. Discovery and development of purine-scaffold Hsp90 inhibitors. Current Topics in Medicinal Chemistry. 6: 1183-91. PMID 16842155 DOI: 10.2174/156802606777812013  0.72
2006 Moulick K, Clement CC, Aguirre J, Kim J, Kang Y, Felts S, Chiosis G. Synthesis of a red-shifted fluorescence polarization probe for Hsp90. Bioorganic & Medicinal Chemistry Letters. 16: 4515-8. PMID 16797988 DOI: 10.1016/j.bmcl.2006.06.025  0.72
2006 Chiosis G, Caldas Lopes E, Solit D. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Current Opinion in Investigational Drugs (London, England : 2000). 7: 534-41. PMID 16784024  0.72
2006 Chu F, Maynard JC, Chiosis G, Nicchitta CV, Burlingame AL. Identification of novel quaternary domain interactions in the Hsp90 chaperone, GRP94. Protein Science : a Publication of the Protein Society. 15: 1260-9. PMID 16731965 DOI: 10.1110/ps.052065106  0.72
2006 Chiosis G, Aguirre J, Nicchitta CV. Synthesis of Hsp90 dimerization modulators. Bioorganic & Medicinal Chemistry Letters. 16: 3529-32. PMID 16621545 DOI: 10.1016/j.bmcl.2006.03.092  0.72
2006 Chiosis G, Rodina A, Moulick K. Emerging Hsp90 inhibitors: from discovery to clinic. Anti-Cancer Agents in Medicinal Chemistry. 6: 1-8. PMID 16475922  0.72
2006 De Martino G, Edler MC, La Regina G, Coluccia A, Barbera MC, Barrow D, Nicholson RI, Chiosis G, Brancale A, Hamel E, Artico M, Silvestri R. New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. Journal of Medicinal Chemistry. 49: 947-54. PMID 16451061 DOI: 10.1021/jm050809s  0.72
2006 Chiosis G. Targeting chaperones in transformed systems--a focus on Hsp90 and cancer. Expert Opinion On Therapeutic Targets. 10: 37-50. PMID 16441227 DOI: 10.1517/14728222.10.1.37  0.72
2006 He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, Wu N, Immormino RM, Gewirth DT, Chiosis G. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. Journal of Medicinal Chemistry. 49: 381-90. PMID 16392823 DOI: 10.1021/jm0508078  0.72
2005 Chiosis G, Brodsky JL. Small molecule microarrays: from proteins to mammalian cells - are we there yet? Trends in Biotechnology. 23: 271-4. PMID 15922078 DOI: 10.1016/j.tibtech.2005.03.011  0.72
2005 Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies P, Chiosis G. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. Journal of Medicinal Chemistry. 48: 2892-905. PMID 15828828 DOI: 10.1021/jm049012b  0.72
2004 Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90: the vulnerable chaperone. Drug Discovery Today. 9: 881-8. PMID 15475321 DOI: 10.1016/S1359-6446(04)03245-3  0.72
2004 Kim J, Felts S, Llauger L, He H, Huezo H, Rosen N, Chiosis G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. Journal of Biomolecular Screening. 9: 375-81. PMID 15296636 DOI: 10.1177/1087057104265995  0.72
2004 Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P, Chiosis G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chemistry & Biology. 11: 787-97. PMID 15217612 DOI: 10.1016/j.chembiol.2004.04.008  0.72
2004 He H, Llauger L, Rosen N, Chiosis G. General method for the synthesis of 8-arylsulfanyl adenine derivatives. The Journal of Organic Chemistry. 69: 3230-2. PMID 15104473 DOI: 10.1021/jo049875c  0.72
2004 Llauger L, He H, Chiosis G. Synthesis of 8-arylsulfoxyl/sulfonyl adenines Tetrahedron Letters. 45: 9549-9552. DOI: 10.1016/j.tetlet.2004.11.009  0.72
2003 Llauger-Bufi L, Felts SJ, Huezo H, Rosen N, Chiosis G. Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorganic & Medicinal Chemistry Letters. 13: 3975-8. PMID 14592488 DOI: 10.1016/j.bmcl.2003.08.065  0.72
2003 Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N. Development of purine-scaffold small molecule inhibitors of Hsp90. Current Cancer Drug Targets. 3: 371-6. PMID 14529388 DOI: 10.2174/1568009033481778  0.72
2003 Huezo H, Vilenchik M, Rosen N, Chiosis G. Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR. Chemistry & Biology. 10: 629-34. PMID 12890536 DOI: 10.1016/S1074-5521(03)00144-3  0.72
2003 Boneca IG, Chiosis G. Vancomycin resistance: occurrence, mechanisms and strategies to combat it. Expert Opinion On Therapeutic Targets. 7: 311-28. PMID 12783569 DOI: 10.1517/14728222.7.3.311  0.72
2003 Yamamoto K, Garbaccio RM, Stachel SJ, Solit DB, Chiosis G, Rosen N, Danishefsky SJ. Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol. Angewandte Chemie (International Ed. in English). 42: 1280-4. PMID 12645064 DOI: 10.1002/anie.200390329  0.72
2003 Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L. 17AAG: low target binding affinity and potent cell activity--finding an explanation. Molecular Cancer Therapeutics. 2: 123-9. PMID 12589029  0.72
2002 Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 100: 3041-4. PMID 12351420 DOI: 10.1182/blood-2002-05-1361  0.72
2002 Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N. Development of a purine-scaffold novel class of hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase Bioorganic and Medicinal Chemistry. 10: 3555-3564. PMID 12213470 DOI: 10.1016/S0968-0896(02)00253-5  0.72
2002 Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. The Journal of Biological Chemistry. 277: 39858-66. PMID 12176997 DOI: 10.1074/jbc.M206322200  0.72
2001 Lucas B, Rosen N, Chiosis G. Facile synthesis of a library of 9-alkyl-8-benzyl-9H-purin-6-ylamine derivatives Journal of Combinatorial Chemistry. 3: 518-520. PMID 11703144 DOI: 10.1021/cc010017t  0.72
2001 Chiosis G, Boneca IG. Selective cleavage of D-Ala-D-Lac by small molecules: Re-sensitizing resistant bacteria to vancomycin Science. 293: 1484-1487. PMID 11520986 DOI: 10.1126/science.1060324  0.72
2001 Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells Chemistry and Biology. 8: 289-299. PMID 11306353 DOI: 10.1016/S1074-5521(01)00015-1  0.72
2001 Chiosis G, Rosen N, Sepp-Lorenzino L. LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family Bioorganic and Medicinal Chemistry Letters. 11: 909-913. PMID 11294389 DOI: 10.1016/S0960-894X(01)00099-3  0.72
2000 Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases Cancer Research. 60: 2090-2094. PMID 10786665  0.72
2000 Chiosis G. Study into the cyclization of an epoxy-alcohol to the energetically disfavored product by peptides from non-biased combinatorial libraries Tetrahedron Letters. 41: 801-806. DOI: 10.1016/S0040-4039(99)02196-6  0.72
1996 Van Axel Castelli V, Cacciapaglia R, Chiosis G, Van Veggel FCJM, Mandolini L, Reinhoudt DN. The uranyl unit as electrophilic catalyst of acyl transfer reactions Inorganica Chimica Acta. 246: 181-193.  0.72
1994 Van Veggel FCJM, Chiosis G, Cameron BR, Reinhoudt DN. Preorganized metallomacrocycles: Selective receptor for NH3 Supramolecular Chemistry. 4: 177-183. DOI: 10.1080/10610279408029470  0.72
1994 Kremer FJB, Chiosis G, Engbersen JFJ, Reinhoudt DN. Improved guanidinium ion-selectivity by novel calix[4]arene and calix[6]arene receptor molecules on CHEMFETs Journal of the Chemical Society, Perkin Transactions 2. 677-681.  0.72
Show low-probability matches.